HUP0401946A2 - Escitalopramot tartalmazó kristályos gyógyszerkészítmény - Google Patents

Escitalopramot tartalmazó kristályos gyógyszerkészítmény

Info

Publication number
HUP0401946A2
HUP0401946A2 HU0401946A HUP0401946A HUP0401946A2 HU P0401946 A2 HUP0401946 A2 HU P0401946A2 HU 0401946 A HU0401946 A HU 0401946A HU P0401946 A HUP0401946 A HU P0401946A HU P0401946 A2 HUP0401946 A2 HU P0401946A2
Authority
HU
Hungary
Prior art keywords
oxalate
escitalopram
well
temperature
crystalline
Prior art date
Application number
HU0401946A
Other languages
English (en)
Inventor
Troels Volsgaard Christensen
Ken Liljegren
Michiel Onne Elema
Lene Andresen
Shashank Mahashabde
Sebastian P. Assenza
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0401946(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HUP0401946A2 publication Critical patent/HUP0401946A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány az escitalopram (nemzetközi szabad név), azaz a jól ismertantidepresszáns hatású citalopram S-enantiomerje oxalátsójának,szabatos kémiai névvel (S)-1-[3-(dimetilamino)propil]-1- -(4-fluorfenil)-1,3-dihidro-5-izobenzofuránkarbonitril-oxalátnakkristályos szemcséire, valamint ilyen kristályos szemcsékettartalmazó, szilárd halmazállapotú gyógyászati készítményekre, továbbáa kristályos szemcsék előállítására vonatkozik. Az escitalopram-oxalátkristályos szemcséinek átlagos szemcsemérete legalább 40 mm, előnyösen50 mm és 250 mm közötti. Az eljárás abban áll, hogy escitalopram-oxalát egy alkalmas oldószer-rendszerrel készült oldatát egy elsőhőmérsékletről fokozatosan lehűtik egy második hőmérsékletre,szabályozott hűtési profilt tartva, és az escitalopram-oxalát említettoldatát beojtják escitalopramoxalát kristályai hozzáadása útján alehűtés során, majd az említett második hőmérsékleten a rendszertadott időn át állni hagyják. Ó
HU0401946A 2001-07-31 2002-07-25 Escitalopramot tartalmazó kristályos gyógyszerkészítmény HUP0401946A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101164 2001-07-31
PCT/DK2002/000513 WO2003011278A1 (en) 2001-07-31 2002-07-25 Crystalline composition containing escitalopram

Publications (1)

Publication Number Publication Date
HUP0401946A2 true HUP0401946A2 (hu) 2005-01-28

Family

ID=8160647

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401946A HUP0401946A2 (hu) 2001-07-31 2002-07-25 Escitalopramot tartalmazó kristályos gyógyszerkészítmény

Country Status (40)

Country Link
US (3) US6916941B2 (hu)
EP (2) EP1522539B1 (hu)
JP (4) JP2005525993A (hu)
KR (1) KR20040028947A (hu)
CN (2) CN1660074A (hu)
AR (1) AR034898A1 (hu)
AT (2) ATE352546T1 (hu)
AU (1) AU2002355624B2 (hu)
BG (1) BG108571A (hu)
BR (1) BR0206164A (hu)
CA (1) CA2451915C (hu)
CO (1) CO5560540A2 (hu)
CY (1) CY1106413T1 (hu)
DE (2) DE60202615T2 (hu)
DK (2) DK1522539T3 (hu)
EA (1) EA006213B1 (hu)
EG (1) EG24206A (hu)
ES (2) ES2233842T3 (hu)
HK (1) HK1070000A1 (hu)
HR (2) HRP20031073A2 (hu)
HU (1) HUP0401946A2 (hu)
IL (2) IL159326A0 (hu)
IS (1) IS7077A (hu)
MA (1) MA27349A1 (hu)
ME (1) MEP2108A (hu)
MX (1) MXPA04000849A (hu)
MY (1) MY126238A (hu)
NO (1) NO328346B1 (hu)
NZ (1) NZ530157A (hu)
PE (1) PE20030304A1 (hu)
PL (1) PL366995A1 (hu)
PT (2) PT1522539E (hu)
RS (1) RS8304A (hu)
SI (1) SI1414435T1 (hu)
TN (1) TNSN04021A1 (hu)
TR (1) TR200400189T2 (hu)
UA (1) UA79930C2 (hu)
UY (1) UY27404A1 (hu)
WO (1) WO2003011278A1 (hu)
ZA (1) ZA200309684B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142926C (zh) 1999-04-14 2004-03-24 H·隆德贝克有限公司 制备西酞普兰的方法
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IL159326A0 (en) 2001-07-31 2004-06-01 Lundbeck & Co As H Crystalline composition containing escitalopram
PE20040991A1 (es) 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
WO2006123243A2 (en) * 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US20070098804A1 (en) * 2005-08-29 2007-05-03 Judith Aronhime Solid particulate tadalafil having a bimodal particle size distribution
EA200801081A1 (ru) 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
EP2086509A1 (en) * 2006-10-20 2009-08-12 Ratiopharm GmbH Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
EP2291177A2 (en) * 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ (1s)−1−[3−(ジメチルアミノ)プロピル]−1−(4−フルオロフェニル)−1,3−ジヒドロイソベンゾフラン−5−カルボニトリル蓚酸塩の製造方法
JP6423133B1 (ja) * 2017-04-10 2018-11-14 東和薬品株式会社 エスシタロプラム医薬組成物
CN107441052A (zh) * 2017-06-21 2017-12-08 山东京卫制药有限公司 一种含有草酸艾司西酞普兰的片剂及其制备方法
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
JP7453859B2 (ja) 2020-06-22 2024-03-21 東和薬品株式会社 エスシタロプラム錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (hu) 1965-03-18
GB1358915A (en) 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
DE3688827T2 (de) 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AU5966196A (en) 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
DE1015416T1 (de) 1997-07-08 2000-10-05 Lundbeck A S Kobenhavn Valby H Verfahren zur herstellung von citalopram
GB9714841D0 (en) 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
JP3813820B2 (ja) * 1997-11-11 2006-08-23 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
WO2000023431A1 (en) 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
CN1142926C (zh) 1999-04-14 2004-03-24 H·隆德贝克有限公司 制备西酞普兰的方法
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
CA2385749A1 (en) * 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
IL159326A0 (en) 2001-07-31 2004-06-01 Lundbeck & Co As H Crystalline composition containing escitalopram

Also Published As

Publication number Publication date
MXPA04000849A (es) 2004-05-14
MA27349A1 (fr) 2005-06-01
HRP20080410A2 (en) 2008-10-31
PT1414435E (pt) 2005-05-31
UY27404A1 (es) 2003-02-28
IS7077A (is) 2003-12-15
EG24206A (en) 2008-10-21
WO2003011278A1 (en) 2003-02-13
AR034898A1 (es) 2004-03-24
EP1414435A1 (en) 2004-05-06
HRP20031073A2 (en) 2004-04-30
JP2012211186A (ja) 2012-11-01
US20030212128A1 (en) 2003-11-13
AU2002355624B2 (en) 2006-02-02
BG108571A (en) 2005-02-28
CA2451915C (en) 2010-09-21
EP1522539A1 (en) 2005-04-13
EP1522539B1 (en) 2007-01-24
JP2011195591A (ja) 2011-10-06
DE60202615T2 (de) 2006-01-12
PT1522539E (pt) 2007-03-30
ES2280892T3 (es) 2007-09-16
DE60202615D1 (de) 2005-02-17
DK1414435T3 (da) 2005-05-09
HRPK20080410B3 (en) 2009-09-30
ATE352546T1 (de) 2007-02-15
CO5560540A2 (es) 2005-09-30
NZ530157A (en) 2007-06-29
NO20040380L (no) 2004-01-28
HK1070000A1 (en) 2005-06-10
SI1414435T1 (en) 2005-06-30
CN1536997A (zh) 2004-10-13
JP2005525993A (ja) 2005-09-02
BR0206164A (pt) 2003-10-28
CN1311819C (zh) 2007-04-25
TNSN04021A1 (en) 2006-06-01
US6916941B2 (en) 2005-07-12
DE60217932T2 (de) 2007-08-30
US20080305164A1 (en) 2008-12-11
TR200400189T2 (tr) 2004-12-21
ES2233842T3 (es) 2005-06-16
NO328346B1 (no) 2010-02-01
UA79930C2 (en) 2007-08-10
EA200400243A1 (ru) 2004-06-24
PE20030304A1 (es) 2003-03-27
IL159326A0 (en) 2004-06-01
CY1106413T1 (el) 2011-10-12
IL159326A (en) 2010-05-31
US7420069B2 (en) 2008-09-02
CA2451915A1 (en) 2003-02-13
KR20040028947A (ko) 2004-04-03
ZA200309684B (en) 2004-12-22
US20050147674A1 (en) 2005-07-07
EP1414435B1 (en) 2005-01-12
JP2010150283A (ja) 2010-07-08
DE60217932D1 (de) 2007-03-15
CN1660074A (zh) 2005-08-31
ATE286730T1 (de) 2005-01-15
PL366995A1 (en) 2005-02-07
MY126238A (en) 2006-09-29
MEP2108A (xx) 2010-02-10
JP4971477B2 (ja) 2012-07-11
JP5719811B2 (ja) 2015-05-20
EA006213B1 (ru) 2005-10-27
RS8304A (en) 2006-12-15
JP5192568B2 (ja) 2013-05-08
DK1522539T3 (da) 2007-05-07

Similar Documents

Publication Publication Date Title
HUP0401946A2 (hu) Escitalopramot tartalmazó kristályos gyógyszerkészítmény
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
NO20085078L (no) Nye forbindelser
NO20030051D0 (no) Ny <gamma>-krystallinsk form av perindopril tert- butylaminsalt, fremgangsmåte for dens fremstilling og farmasöytiske sammensetningerinneholdende den
ATE429210T1 (de) Orale flüssige zusammensetzungen
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
MY148297A (en) Process for modifying drug crystal formation
FR2780403B3 (fr) Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
HUP0401451A2 (hu) Eljárás escitalopram elõállítására
NO20030050L (no) Ny <beta>-krystallinsk form av perindopril tert- butylaminsalt, fremgangsmåte for dens fremstilling og farmasöytiske sammensetningerinneholdende den
CY1107451T1 (el) Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου
BR0211739A (pt) Novas formas polimórficas cristalinas de cloridrato de lercanidipina e processo para preparação das mesmas
HU229456B1 (en) Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
JP2005538045A5 (hu)
HUP0303737A2 (hu) 6-helyzetben szubsztituált indolinonok és alkalmazásuk kináz inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300389A2 (hu) A kabergolin II. kristályformája, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
HUP0204005A2 (hu) Pravastatin-nátrium új módosulatai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200601641A1 (ru) Кристаллическая композиция, содержащая оксалат эсциталопрама
ATE308537T1 (de) Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69300453D1 (de) Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen.
EE200100639A (et) Aminoalküül-asendatud bensodioksaani, bensofuraani või bensopüraani derivaadid, nende valmistamismeetod, farmatseutiline kompositsioon ja selle valmistamismeetod
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
MXPA04001030A (es) Proceso para la preparacion de isobenzofuranos 5-sustituidos.
ATE282726T1 (de) Herstellung von verbindungen auf basis von cu-in- se phasengleichgewichten

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees